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Abstract
Background: Dystroglycan is a ubiquitously expressed cell adhesion receptor best understood in its role as part of the
dystrophin glycoprotein complex of mature skeletal muscle. Less is known of the role of dystroglycan in more fundamental
aspects of cell adhesion in other cell types, nor of its role in myoblast cell adhesion.
Principal Findings: We have examined the role of dystroglycan in the early stages of myoblast adhesion and spreading and
found that dystroglycan initially associates with other adhesion proteins in large puncta morphologically similar to
podosomes. Using a human SH3 domain phage display library we identified Tks5, a key regulator of podosomes, as
interacting with b-dystroglycan. We verified the interaction by immunoprecipitation, GST-pulldown and immunfluorescence
localisation. Both proteins localise to puncta during early phases of spreading, but importantly following stimulation with
phorbol ester, also localise to structures indistinguishable from podosomes. Dystroglycan overexpression inhibited
podosome formation by sequestering Tks5 and Src. Mutation of dystroglycan tyrosine 890, previously identified as a Src
substrate, restored podosome formation.
Conclusions:We propose therefore, that Src-dependent phosphorylation of b-dystroglycan results in the formation of a Src/
dystroglycan complex that drives the SH3-mediated association between dystroglycan and Tks5 which together regulate
podosome formation in myoblasts.
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Introduction
Cellular adhesion, migration and invasion are fundamental
properties of most cell types during development and normal
tissue/cellular function. For these cells, cell-cell and cell-substrate
adhesion is essential to the maintenance of polarity, differentiation
and tissue architecture. During development some cells, including
myoblasts [1], migrate large distances. Others, such as macro-
phages are actively migratory as part of their normal function. In
both instances, in order to migrate these cells need to overcome
the physical and biochemical barrier of the extracellular matrix
(ECM). Matrix degradation is most often seen at specialised
adhesion sites known as podosomes or adhesion/protrusion sites
known as invadopodia, reviewed in [2]. Such sites are proposed to
mediate the polarised migration of cells that cross ECM
boundaries. Podosomes are transient peripheral adhesion struc-
tures often formed in migrating tumour and other cells and
contain a dense actin-rich core and a ring of actin regulatory/
binding and adhesion proteins. Podosome assembly is regulated by
non-receptor tyrosine kinases such as Src [3] and by Rho family
GTPases [4,5]. Related structures called invadopodia contain a
similar complement of proteins, but are larger, centrally located
and more persistent. In addition to which they have the ability to
invade the matrix beneath them presumably as a prelude to tissue
invasion [6]. We have demonstrated a key role for dystroglycan
(DG) in cell migration and adhesion [7,8] and recently identified
DG as a component of podosomes.
Dystroglycan was first identified as a laminin binding protein
from brain, and as part of the dystrophin glycoprotein complex
(DGC) of skeletal muscle [9,10]. DG is a transmembrane adhesion
receptor comprising a- and b-subunits that are post-translationally
cleaved from a single precursor peptide and subjected to extensive
and functionally important glycosylation. The extracellular a-
subunit mediates the link to laminin in the ECM and also binds
the transmembrane b-subunit through non-covalent interactions,
reviewed in [11]. As we have shown previously, the intracellular
domain of b-DG mediates direct and indirect attachments to the
actin cytoskeleton via a number of actin binding proteins, and also
makes associations with a number of signalling and adaptor
proteins (see [12] and references therein). Loss of DG or any of the
associated DGC proteins in muscle leads to loss of the entire
complex with loss of membrane-cytoskeleton stabilisation and
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consequent muscle damage [13]. DG is a key component of the
DGC of skeletal muscle and plays an important role in costameric
cell adhesion. By anchoring the costamere, the principle adhesion
structure along the length of the individual myofibres, stably to the
ECM, DG serves to preserve membrane integrity by protecting
the cell against contraction induced membrane damage. In
addition a number of signalling functions are also associated with
DG [14]. In addition to a specific role in the maintenance of
muscle integrity, DG has a more ubiquitous role in cell adhesion,
signalling and polarity, and DG protein levels are reduced in
almost all epithelial tumours so far examined [15]. We have
identified DG as a component of small adhesion puncta during the
early stages of myoblast spreading and characterised these puncta
as podosomes containing a regulatory complex comprising
dystroglycan, Tks5 and Src.
Materials and Methods
Cell culture
Mouse myoblast cells (H-2Kb-tsA58) were maintained as
described previously [16]. Myoblast cell lines that stably expressed
dystroglycan-GFP, GFP, an shRNA against DG and a sense
strand control shRNA were generated using retroviral infection as
described previously [8,12]. With the exception of the cytoplasmic
domain of b-DG myc construct (cbDG-myc) all other dystroglycan
expression constructs used including point mutants, whether fused
to myc or GFP comprised full length a- and b-dystroglycan. A7r5
smooth muscle cells were grown in DMEM+10% FCS at 37uC in
5% CO2. Where required cells were plated onto glass coverslips
coated overnight with 5 mg/ml in PBS of ECM protein; gelatin,
laminin, fibronectin, poly-L-lysine (Sigma) or N-terminally-His-
tagged E3 LG4-5 module of laminin a2 chain; [17] a generous gift
from Erhard Hohenester (Imperial College, London). Uncoated
regions were blocked with 1% BSA for 1 hour at room
temperature, rinsed once with PBS and used within 3 hours of
preparation. For matrix degradation assays, porcine type A gelatin
(Sigma; 0.2% in 50 mM Na2B4O7 pH 9.3) was incubated with
rhodamine B isothiocyanate (70 mM; Sigma) at room temperature
for 2 hours. Following extensive dialysis, coverslips were coated in
rhodamine-gelatin by immersion for 5 minutes. Excess was
drained off and coverslips fixed in 0.5% (v/v) gluteraldehyde for
15 min. Coverslips were washed 3 times in PBS, incubated in ice-
cold NaBH4 (3 min) with agitation, washed with PBS, and stored
in 70% ethanol. Prior to use coverslips were dried and incubated
in normal growth medium for 1 h. Podosomes/invadopodia were
induced by addition of 2.5 mM phorbol 12, 13-dibutyrate (PDBu;
Sigma) to the growth medium for 30 min (myoblasts) or 1 h
(A7r5). Inhibition of Src was achieved by treatment in normal
culture medium containing 10 mM PP2 (Calbiochem) for 1 hour
prior to immunostaining. Tissue culture cells were fixed and
stained for immunfluorescence microscopy as described previously
[18]. Percentage of podosome containing cells, where quantified,
were estimated in at least 100 cells in three independent
experiments per treatment. The following antibodies were used
for immunfluorescence microscopy at the indicated dilutions:
MANDAG2 monoclonal anti-b-DG 1:25 (1:350 for western 1:10
for IP) [19]; 1709, anti-pY892 b-DG 1:10 [20]; Vinculin, clone
V9131 1:400 and Talin, clone 8D4 1:100 (Sigma-Aldrich);
Phosphotyrosine PY20 1:1000 and Paxillin 1:1000 (Transduction
Labs); Cortactin, clone 4F11 1:100 (Upstate Biotech); Tks5 1:200
(1:20 for IP) and Myc clone 9E10 1:100 (Santa Cruz Biotech);
Tks5 1:500 (1:2000 for western) [21]; Ezrin 1:1000 (Dr Sam
Crouch, University of Dundee); Plectin clone 9F10 1:10 000
(Gerhard Wiche, Vienna); Actin-related protein 1:500 (Laura
Machesky, CRUK Glasgow); Pan-Src 1:40 (Calbiochem); Active
Src (dual-phosphorylated) 1:1000 (Cell Signalling); Glutathione-S-
transferase 1:5000 for western (SJ Winder unpublished); fluores-
cent phalloidins to detect F-actin 1 mg/ml (Molecular Probes) and
fluorescent species specific secondary antibodies 1 mg/ml (Vector
Labs).
For live cell imaging, myoblast cells plated on glass bottom
culture dishes were transiently transfected as described above with
GFP-actin [22] and imaged at 30 second intervals on either a
Leica DMIRE2 using 636 lwd optics. Images were captured by
CCD and converted to Quicktime movies by importing individual
frames into ImageJ. Time lapse recording was also performed on a
DeltaVision RT using 636 oil immersion optics. Movies were
generated directly using the SoftWorx package.
Assays for protein-protein interaction
Cytoplasmic domain of mouse b-DG expressed in E. coli and
purified as described previously [23], was used to screen a phage
display library comprising an essentially complete collection
(n= 296) of human SH3 domains using the protocol described
in Kärkkäinen et al. [24]. In short, recombinant b-DG was
adhered to 6-well plastic plates (1 mg/ml in PBS incubated
overnight at 4uC) and blocked with 5% (w/v) milk in PBS/0.05%
(v/v) Tween 20. The wells washed briefly with PBS before
1010 pfu of infectious SH3 phage library was added per well. After
2 hours of incubation the wells were washed four times with PBS/
0.05% Tween 20 and once with PBS followed by addition of log
phase E. coli TG1 cells to be infected during 1 h incubation. A
fraction of the infected cells were plated on ampicillin plates, and
the rest of them put into culture and infected with M13KO7
helper phage (56108 pfu/ml) to generate a secondary infectious
SH3 phage library. After selection of b-dystroglycan-binding
phages as above the SH3 domains in the ampicillin resistant
colonies obtained were identified by sequencing.
GST-fusion proteins corresponding to the 3rd and 5th SH3
domains of Tks5 were generated by PCR, expressed in E coli and
purified on glutathione Sepharose according to the manufacturers
instructions (GE Healthcare). To evaluate binding of b-DG to the
GST-SH3 domains, myoblast lysate prepared in radio immune-
precipitation assay (RIPA) buffer was passed over a GST-SH3
domain affinity column. Following extensive washing bound DG
was eluted with the GST-SH3 domain using 20 mM glutathione.
Fractions were separated by SDS-PAGE and analysed by western
blotting as described previously [7]. Immunoprecipitation assays
were carried out on myoblast extracts in RIPA buffer at 4uC
overnight, following extensive washes and a final stringent wash in
RIPA buffer containing 0.6 M LiCl2, bound proteins were
analysed by SDS-PAGE and western blotting as above.
Cell fractionation experiments were performed as described
previously (Spence et al., 2004). Briefly cells were disrupted in a
1% CHAPS buffer to release membrane associated and cytosolic
proteins. Following centrifugation the resultant pellet was further
extracted with 1% Triton and centrifuged to form a Triton-
insoluble cytoskeletal pellet fraction, and a residual Triton soluble
fraction.
GFP-Tks5-mito construct
The GFP-Tks5-mito construct was generated by a two-step
process. GFP was fused directly onto the N-terminus of Tks5, and
an additional linker was added to the C-terminus of Tks5
separating Tks5 and the mito sequence. As first step, the GFP-
mito vector was generated by cloning the cDNA of the
mitochondrial targeting sequence of ActA [25] into pEGFP-C2
(Clontech), similarly to a prior strategy [26]. The additional linker
Dystroglycan in Podosomes
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GSTSGSGKPGSGEGSTKG [27] was inserted into the EcoRI
site of the GFP-mito vector, between the GFP and the mito
sequence. Finally, the human cDNA of Tks5 (generous gift from S.
Courtneidge, La Jolla) was amplified by PCR using the following
primers: FWD: 59-ATG CTC GAG AAT GCT CGC CTA CTG
CGT GCA-39 and REV: 59-AGG AAG CTT CCG TTC TTT
TTC TCA AGG TAG TTG-39, and cloned into the GFP-mito
vector via XhoI-HindIII restriction sites.
Results
Dystroglycan in adhesion puncta and podosomes
Whilst much is known about the role of dystroglycan in mature
differentiated skeletal muscle [28], less is known about the
functions of DG in cell adhesion in developing muscle [1]. We
therefore examined the role of DG in the formation of cell
adhesions during spreading and adhesion of myoblasts. During the
early phases of cell spreading, and independent of the substrate on
which the cells were spreading on, DG could be seen in relatively
large and densely staining puncta (Figure 1). These puncta were
often located more centrally, and appeared morphologically
distinct from peripheral focal adhesion-like structures. Whilst both
a- and b-dystroglycan as well as utrophin co-localised in these
puncta, other more traditional adhesion proteins including
vinculin, talin and FAK as well as the more generic phospho-
tyrosine also typically seen in adhesion structures were also
localised in the puncta (Figure 1). Interestingly, neither a- and b-
dystroglycan nor utrophin appeared to localise in more peripheral
focal adhesion type structures, compare vinculin staining in
Figure 1. The dystroglycan-staining puncta do not appear
morphologically to resemble focal adhesions and the differential
staining of dystroglycan also suggests that the puncta are somehow
different to focal adhesions stained by vinculin. Whilst it is possible
that the puncta are focal contacts [29,30] their more central
position in the cell and their relatively large size would argue
against this. One other adhesion structure that has a larger and
rounder morphology is the podosome, typically found in cells of
the monocyte lineage, osteoclasts and smooth muscle cells [6].
Myoblasts have not previously been demonstrated to form
podosomes. Therefore in order to determine if myoblasts could
form podosomes, we subjected well-spread myoblasts to stimula-
tion with the phorbol ester PDBu, in order to activate Src
downstream of PKC as part of a pathway leading to podosome
formation [31]. Myoblast cells were then co-stained for classical
markers of podosomes: actin and cortactin (Figure 2A). Podosomes
contain a dense actin-rich core surrounded by a loose meshwork of
adhesion proteins and actin binding and regulatory proteins [6]. In
this regard the structures formed in myoblast cells appear
morphologically similar to podosomes seen in other cell types
[2] (Figure 2B) and thus henceforth will be considered as
podosomes. Podosome formation was also independent of the
substrate that the cells were adhered to. Actin- and cortactin-
containing structures formed in a band behind the leading edge of
the cell equally well on glass, gelatin, fibronectin and whole or E3
fragment of laminin, compared to the unstimulated cell
(Figure 2A). A further characteristic of podosomes and structurally
related invadopodia, is the ability to degrade the matrix beneath
the adhesion site [6]. The dystroglycan-containing structures in
myoblasts appear to share this property too, in that there are zones
of clearance of rhodamine-gelatin beneath the dystroglycan-
containing adhesion structures (Figure 2C). In addition, DG co-
localised in podosomes with plectin and integrin, other proteins
known to be resident in podosomes [6,32] (Figure S1A). Other
well-characterised myoblast cells such as C2C12 [33] were also
able to form podosomes in response to PDBu (Figure S1B). To
ascertain whether or not the localisation of DG to podosomes was
Figure 1. Spreading myoblasts form DG rich adhesion puncta. Myoblast cells were seeded onto tissue culture plastic and allowed to spread
for one hour before fixation and staining for b-dystroglycan, and counterstained with one of the indicated cell adhesion proteins/markers. In all cases
b-DG was colocalised in dense puncta either peripheral or more central to the cell, reminiscent of podosomes. Both a-dystroglycan and utrophin,
components of a recognised adhesion structure, co-localised with b-dystroglycan. Other markers of classical focal adhesions such as vinculin, talin,
FAK and the generic marker phospho-tyrosine also marked the b-dystroglycan containing puncta. Vinculin also clearly labelled peripheral focal
adhesions, distinguishing them from the b-dystroglycan puncta. Scale bars 20 mm.
doi:10.1371/journal.pone.0003638.g001
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unique to myoblasts we also examined the localisation of DG in
A7r5 smooth muscle cells in response to PDBu stimulation. A7r5
cells are a well-established model for podosomes and as shown in
Figure S1C, DG also colocalised in podosomes with actin,
cortactin or vinculin. Thus it appears that myoblasts can form
podosomes and that dystroglycan is localised to podosomes along
with other well recognised podosome proteins. Furthermore as can
be seen from movies of myoblast cells expressing GFP-b-actin
(Movie S1, S2, S3), podosome structures and podosome dynamics
appear qualitatively similar to GFP-b-actin movies from A7r5 cells
for example see [34] and have similar dynamics to DsRed-SM22
(used to label F-actin) podosomes in A7r5 cells [35,36].
Dystroglycan interacts with Tks5
Given the apparent localisation of dystroglycan to podosomes
(Figure 1 and Supp Figure 1) but not to focal adhesions (Figure 1)
we reasoned that a unique factor may be targeting dystroglycan to
podosomes. The DG cytoplasmic domain comprises 25% proline
residues which form six PxxP motifs suggestive of potential SH3
domain interaction sites. Given the importance of SH3 domain
adaptors in mediating connections between proteins at adhesion
sites [37] we undertook a human proteome-wide SH3 domain
phage-display screen using the cytoplasmic domain of b-DG as an
affinity ligand, in order to identify potential adaptor proteins. In
agreement with the predicted SH3 binding sites, significant
enrichment of clones from the SH3 domain displaying phage
library was observed upon selection with b-DG, some of these
currently form the basis of ongoing studies in our laboratories.
Sequencing of the clones identified the third SH3 domains of the
homologous adapter proteins Tks5 and Tks4 [38] among the most
frequent b-DG binders. Although the adapter protein Grb2 has
been suggested in the literature as an SH3-containing binding
partner of b-dystroglycan [39], neither of the two SH3 domains of
Grb2 were found among the affinity selected clones. When we
produced homogeneous phage preparations carrying either the
third SH3 domain of Tks5, or the N- or C-terminal SH3 of Grb2,
only Tks5 but not Grb2 SH3-displaying phages bound to b-
dystroglycan-immobilized plates better than to negative control
plates (data not shown). Moreover, no b-dystroglycan binding
could be observed by Grb2 SH3 domains expressed as
recombinant GST fusion proteins (data not shown). Thus, the
failure to identify Grb2 SH3 domains in the phage library screen
was in agreement with undetectable b-dystroglycan binding
capacity in these individual assays, suggesting that the previous
studies on Grb2 binding to b-dystroglycan [40] may have
overestimated the affinities of these SH3 interactions. Based on
use of this library for affinity selection of a large number of ligands,
some with no known partners and some with well characterized
SH3 partners, it has become clear that only moderately strong
binding (with reference to SH3 binding in general) is needed in
order to positively select individual SH3 clones from this library.
Based on Kd values previously established for SH3 interactions
that we have selected or failed to select in our screens, we have
estimated that a binding affinity of approximately 10–20 mM
would be generally required to support positive selection.
Considering that selection of the third SH3 of Tks4 and Tks5
was relatively inefficient, we would anticipate the affinity in these
cases to be in the 5–10 mM range. Compared to some other
protein interactions, this would be rather weak, but among SH3-
mediated interactions represents a perfectly respectable value.
Tks5 is a 140 kDa protein comprising an amino terminal PX
domain followed by five SH3 domains and was first identified in a
screen for Src substrates [38]. Importantly Tks5 has also been
found to associate with ADAMs family proteases and to localise to
podosomes in response to Src activation [21,41]. Tks4 was
identified from databases and like Tks5 has a PX domain but lacks
the fourth of the five SH3 domains. More recently it has been
suggested that Tks5 may undergo alternative splicing to remove
the first SH3 domain [42], however the relationship between this
putative alternatively spliced Tks5 and Tks4 are not clear. No
further evidence of a role for Tks4 is available, we therefore
concentrated our efforts on the Tks5 SH3 domain interaction.
We verified an interaction between Tks5 and b-DG by
reciprocal immunoprecipitation from myoblast lysates. As shown
in figure 3A, antibodies against either b-DG or Tks5 were able to
immunoprecipitate the other protein. To further substantiate a
role for the 3rd SH3 domain we used a GST-SH3 pulldown to
recover b-DG from myoblast lysates. DG was recovered
specifically with the 3rd but not the 5th SH3 domain of Tks5
fused to GST. Significantly the b-DG bound to the Tks5 was only
recognised by an anti-phospho b-DG antibody that is able to
recognise DG that is phosphorylated on tyrosine 890 (Y890). A
monoclonal antibody that recognises a similar epitope, but that
can’t bind to b-DG that is phosphorylated on Y890 did not detect
any b-DG in either pulldown (Figure 3B). This result suggests that
not only is Src activation necessary for podosome formation, and
for the recruitment of Tks5 to podosomes, but that when b-DG is
associated with Tks5 in cells, it too is phosphorylated on tyrosine at
Y890. In order to demonstrate an interaction between DG and
Tks5 in a cellular context, we employed a GFP-tagged Tks5
construct fused with a mitochondrial targeting sequence at its
amino terminus. As can be seen in Figure 3C, the mito-Tks5-GFP
construct was efficiently targeted to mitochondria and localised
extensively with mito-tracker red staining in the myoblast cells. We
then co-expressed the mito-Tks5-GFP construct with a construct
comprising the cytoplasmic domain of b-DG only with an amino-
terminal Myc tag. As we have demonstrated previously this
construct is entirely cytosolic [8,12], and therefore its localisation
should respond to that of a binding partner that was localised to a
discrete domain such as the mitochondrion. As can be seen, this is
indeed the case; the cytoplasmic Myc-cb-DG construct is
colocalised with the mito-Tks5-GFP (Figure 3D) rather than
appearing diffusely in the cytoplasm (Figure 3E) substantiating an
interaction between the two proteins. We further verified the
association between Tks5 and DG by immunfluorescence
localisation of the two proteins with F-actin in myoblasts before
and after stimulation with PDBu. As can be seen in Figure 4,
whilst there is a faint and indistinct area of colocalisation between
Tks5 and b-DG towards the leading extremities of unstimulated
myoblasts, which may correspond to the podosome cluster
Figure 2. Myoblasts form podosomes in response to PDBu. To determine if myoblast cells could form podosomes, myoblast cells were
allowed to adhere and spread on various substrates, and stimulated with PDBu for 30 min and fixed and stained for the podosome markers cortactin
(green) and F-actin (red). Myoblasts formed peripheral actin and cortactin containing puncta on all substrates tested. An unstimulated cell grown on a
glass coverslip is also shown for comparison (A, bottom right panel). These structures are morphologically indistinguishable from podosomes (A). The
structures appeared columnar within the cell and cortactin was localised around a more central actin core as seen in the Z section of the zoomed
region of B. The identity of the DG and actin-rich puncta as podosomes/invadopodia was further substantiated by the degradation of rhodamine-
gelatin beneath them, seen as darker areas of reduced rhodamine gelatin (red in merge, arrowed) that are coincident with DG localisation (green in
merge, arrowed) and F-actin (blue in merge). Scale bars 20 mm in A and 10 mm in B, C, 2 mm in zoomed region of B.
doi:10.1371/journal.pone.0003638.g002
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Figure 3. Interaction of DG with Tks5. A. b-DG (43 kDa) was co-immunoprecipitated from myoblast extracts with Tks5 antiserum and Tks5
(150 kDa) was co-immunoprecipitated with b-DG antibodies. Affinity purification of b-DG from myoblast extracts using the 3rd and 5th SH3 domains
of Tks5 fused to GST revealed a specific interaction with only the 3rd SH3 domain (B). Western blots show peak fractions eluting from the GST-SH3
column, furthermore the b-DG recovered from the GST-SH3 column was preferentially recognised by antibodies that recognise the tyrosine
phosphorylated form of b-DG (pDG) and not the non-phosphorylated form (DG). A GFP-tagged Tks5 construct (mito-Tks5-GFP; C) that was targeted
to the mitochondria in myoblast cells, was also able to recruit a myc-tagged b-DG cytoplasmic domain (myc-CbDG) to the mitochondria (D) indicating
an association between the two proteins in a cellular context. Both myc-CbDG is diffusely distributed when expressed alone as is Tks5-GFP in the
absence of PDBu, but in the presence of PDBu clearly targets to podosome structures (E). Scale bars 10 mm.
doi:10.1371/journal.pone.0003638.g003
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precursors described by Matsudaira and colleagues [43], following
PDBu stimulation all three proteins colocalise robustly to distinct
podosome structures behind the leading edge of the cell. And as in
typical podosome structures, there is a clear actin core with a more
diffuse and wider distribution of dystroglycan and Tks5 (Figure 4
inset).
Altering dystroglycan expression levels modulates
podosome assembly
If as proposed Tks5 is a ‘master regulator’ of podosome
assembly [21], and DG also associates with Tks5, DG may also
have a regulatory role in the podosome assembly process. In order
to address this we examined myoblast cells either overexpressing
or depleted for DG (Figure 5A–C). As determined by assessing the
characteristic actin morphology of podosomes and compared to
control cells, siRNA-mediated depletion of DG to 50% of
endogenous levels in myoblast cells had a modest but statistically
significant effect on the number of cells producing podosomes in
response to PDBu. By contrast, over-expression of DG (tagged
with either Myc or GFP) dramatically and completely abolished
the ability of myoblasts to form podosomes following PDBu
stimulation (Figure 5D). In both dystroglycan knockdown and
dystroglycan overexpressing cells there was a reduction in Tks5 to
an approximately equal level. But despite this reduction in Tks5,
the levels of reduction did not correlate with the change in
podosome levels in these cells. Thus the effect on podosome
assembly of altering DG expression levels either up or down was
not a simple consequence of affecting Tks5 levels in the cell
(Figure 5B,C) as Tks5 levels were equivalent in both knockdown
and overexpressing cells. We hypothesised therefore, that in over-
expressing DG we are potentially titrating out factors such as Tks5
that are crucial to podosome formation. The relative levels of Tks5
and dystroglycan would therefore appear to be as important in the
regulation of podosome assembly as the actual levels of each
protein. From this one could propose that podosome formation
should be restored in cells overexpressing DG by the concomitant
overexpression of Tks5 in the same cell, restoring the ratio of
dystroglycan to Tks5. By co-transfecting myoblasts with Tks5-GFP
and DG-Myc we could observe a restoration of podosome
formation in response to PDBu, but only once Tks5 overexpres-
sion reached some threshold level of expression that balanced the
level of DG-Myc overexpression and permitted podosome
formation (Figure 6A). However, if DG-myc levels predominated
over Tks5-GFP, podosome assembly is inhibited (Figure 6B).
Quantification of the relative fluorescence intensity for the two
fluors (GFP for Tks5 and rhodamine for DG-Myc) per mm2 of cell
area in the cells in Figure 6A,B revealed that a fluorescence ratio of
DG:Tks5 of 1:0.6 was permissive for podosome formation,
whereas a DG:Tks5 fluorescence ratios of 1:0.47 or 1:0.2 was
inhibitory to podosome formation. These ratios represent ratios of
fluorescence and not ratios of the actual proteins, but nonetheless
changing the amount of dystroglycan relative to Tks5 appears to
alter the ability of cells to form podosomes in a ‘dose-dependent’
manner (Fig. 6C). These data suggest the existence of a finely
tuned regulatory balance between dystroglycan and Tks5 in
podosome assembly.
Src phosphorylation of dystroglycan is required for
podosome formation
The dominant-negative effect of excess DG on podosome
formation provided a useful tool to reveal functionally important
regions of dystroglycan involved in podosome formation. By
mutating potential binding sites or phosphorylation sites within the
cytoplasmic domain of b-DG we could also potentially restore
podosome formation by inhibiting the dominant-negative effect of
DG overexpression. We therefore mutagenised potential tyrosine
phosphorylation sites and proline residues in the SH3 domain
binding consensus PxxP motifs within the b-DG cytoplasmic
domain that might mediate SH3 domains interactions with Tks5.
As can be seen in Figure 7, most mutations did not significantly
Figure 4. DG and Tks5 localise to podosomes in myoblasts.
Myoblast cells, untreated (2) and following stimulation with PDBu for
30 min (+) were stained for endogenous b-DG (red), Tks5 (green) and F-
actin (blue). Unstimulated cells exhibit only faint b-DG and Tks5
localisation toward the periphery in cellular protrusions, potentially in
podosome cluster precursors [43]. Following stimulation, b-DG and Tks5
were clearly localised along with F-actin to podosome structures
following stimulation. The actin staining can be seen clearly to form a
more central core to the podosome with Tks5 and dystroglycan around
the periphery (inset). Scale bar 20 mm.
doi:10.1371/journal.pone.0003638.g004
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reduce the inhibition of podosome formation compared to control,
as dystroglycan-GFP carrying these mutations still had a
dominant-negative effect. This was not due to the constructs
failing to express as can be seen from the inset, the levels of DG-
GFP, despite being a transient expression, are relatively similar.
The fact these mutants did not behave exactly like wild-type and
completely inhibit podosome formation, may reflect short range
conformational effects induced by the mutations that perturbed
interactions in neighbouring regions of the b-dystroglycan
cytoplasmic domain. However mutations in Y890 restored
podosome formation in myoblasts suppressing the dominant-
negative effect of over-expressing dystroglycan-GFP (Figure 7).
This result suggests that the phosphorylation of Y890 by Src is an
important event in podosome formation. Overexpression of
Y890A DG significantly restored podosomes to 70% of control
levels, whereas mutation of other tyrosine residues or mutation of
potential SH3 binding sites did not significantly affect podosome
formation (Figure 7). These results highlight the importance of
phosphorylation of b-DG Y890 in podosome assembly and
corroborate the finding that DG associated with Tks5 is tyrosine
phosphorylated (Figure 3B). Earlier work has shown dystroglycan
Y890 to be a substrate for Src family kinases. We therefore treated
early spreading myoblast cells with the Src inhibitor PP2 to
observe the effect on podosome assembly. Compared to untreated
cells, PP2 completely prevented the formation of the dystroglycan-
rich puncta or podosomes instead DG was localised to the cell
periphery along with actin and cortactin (Figure 8AB). As we have
shown previously inhibition of Src does not affect focal adhesion
formation per se [44], accordingly paxillin, talin and vinculin are
all visible in peripheral focal adhesion-like structures (Figure 8AB),
rather Src activity appears to be essential for focal adhesion
turnover or disassembly [45]. By contrast in podosomes, Src
activity appears to be required for the phosphorylation of Tks5
and b-DG in podosome assembly. Phosphorylation of DG Y890
would form a potential SH2 domain interaction site and DG
phosphorylated at this site has been demonstrated previously to
interact with Src itself [46]. We therefore carried out cell
fractionation experiments in cells expressing different levels of
dystroglycan and examined the distribution of dystroglycan and
Src between cytoplasmic, membrane and cytoskeletal fractions.
Due to its association with the actin cytoskeleton, DG is not readily
extracted from membranes by Triton, but rather partitions with
the insoluble cytoskeletal fraction [47]. We therefore utilised a
protocol first extracting in CHAPS to release DG from the
membrane, followed by a triton extraction step to precipitate the
cytoskeleton and associated proteins in the triton insoluble
Figure 5. DG over-expression abolishes podosome formation. Quantification of dystroglycan and Tks5 protein levels in control myoblast cells
(wild-type), cells stably expressing GFP-tagged full-length DG (DG-GFP), shRNA against DG (knockdown) or a control shRNA (sense). Dystroglycan
levels for the four cell lines are shown in A, with corresponding Tks5 levels in B. Whilst dystroglycan levels were increased by 2.3-flod and decreased
by half in overexpressing and knockdown cells respectively, Tks5 levels were reduced by approximately 33% in both cases. Wild-type, sense,
knockdown and myoblasts transiently expressing a myc-tagged DG construct were induced to form podosomes with PDBu and the number of cells
exhibiting podosomes counted following fixation and staining. DG depletion caused a modest reduction in cells with podosomes compared to
control, whereas DG over-expression completely abolished podosome formation. (C,D; mean6SEM).
doi:10.1371/journal.pone.0003638.g005
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Figure 6. The dystroglycan/Tks5 ratio is important for podosome formation. Wild-type myoblast cells were co-transfected with myc-DG
and Tks5-GFP and induced to form podosomes by stimulation with PDBu. In cells co-expressing both myc-DG and Tks5-GFP, podosomes were only
formed when Tks5 expression was high, as judged by myc staining relative to GFP fluorescence; relative fluorescence ratio DG:Tks5 1:0.59 (A lower
panels). However when myc-DG staining (red) predominated over GFP, podosomes were not formed in response to PDBU. B. cells marked in the
merged image have DG:Tks5 ratios of a. 1:0.6; b, 1:0.47; c, 1:0.2. Cells are also stained for F-actin (blue). Scale bars are 10 mm. Quantitative analysis of
dystroglycan-myc and Tks5-GFP ratios in transiently transfected cells reveal a ratio of Tks5:DG that is permissive for podosome formation (C).
Numbers above each column refer to numbers of cells falling within the given ratio of DG:Tks5.
doi:10.1371/journal.pone.0003638.g006
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fraction. This method has been employed with previous success to
extract ERM family proteins and dystroglycan [48,49]. Overex-
pression of DG results in increased levels of free DG in the
CHAPS soluble fraction ([8]; Figure 9A–D). Furthermore,
compared with the cytoskeleton associated (triton insoluble)
dystroglycan a greater proportion of the CHAPS soluble DG is
phosphorylated on Y890. In control cells the distribution of Src is
almost exclusively in the triton insoluble fraction, but in cells
overexpressing DG-GFP, Src localisation switches dramatically to
the CHAPS soluble fraction. It would therefore appear that Y890
phosphorylation results in the creation of an SH2 domain binding
site which also recruits Src to the CHAPS soluble fraction
(Figure 9A,). This is supported by the finding that Src can be co-
immunoprecipitated with both Tks5 and dystroglycan, suggesting
the existence of a ternary complex between Tks5, Src and
dystroglycan (Figure 9E). DG overexpression can therefore
redirect the regulatory functions of both Tks5 and Src, the
combined effects of which result in the inhibition of podosome
formation. This adds further support to the idea that levels of
dystroglycan must be finely balanced to maintain an appropriate
level of scaffolding and signalling to regulate podosome formation.
Discussion
Dystroglycan is a ubiquitously expressed laminin receptor
having a key role in branching epithelial morphogenesis and the
maintenance of membrane stability in mature skeletal muscle. But
its role in early stages of muscle development or in early stages of
myoblast adhesion, spreading and migration are not known.
Dystroglycan is clearly present at the early stages of myoblast
migration [1], but mice specifically lacking dystroglycan in
myoblasts at these stages have not been developed due to the
early embryonic lethality of DAG1 null embryos [50]. Further-
more, in chimaeric mice with skeletal muscle dystroglycan
deficiency, or mice with a conditional knockout of dystroglycan
in their skeletal muscles [51,52], myoblast migration early in
development would not be expected to be affected.
Our previous studies have highlighted the importance of
adhesion mediated signalling leading to the phosphorylation of
dystroglycan on a key regulatory tyrosine - Y890 in mouse (Y892
in human) [7,20]. Tyrosine phosphorylation of dystroglycan, as is
the case with many other adhesion receptors, is involved in
regulating the connection to the cytoskeleton in this case via
dystrophin or utrophin [7,20] but not with some other binding
partners such as caveolin [53,54]. Furthermore, studies from the
Lisanti group have demonstrated that Y890 is a substrate of Src
family kinases and in addition phosphorylation of Y890 by Src
provides an SH2 domain interaction site for Src itself and other
tyrosine kinases or adaptor proteins including Fyn, Csk, Nck, and
Shc [46]. Whilst previous studies have identified a-dystroglycan in
focal adhesion and cell adhesion type structures [49,55], and its
intracellular linker utrophin in focal adhesions [56] there is little
convincing evidence for b-dystroglycan in such structures even
though it is presumed to be there to link between a-dystroglycan
and utrophin. In this study we have identified a- and b-
dystroglycan with utrophin in adhesion structures in spreading
myoblasts. But these adhesion structures have a morphology more
typical of podosomes rather than focal adhesions or focal contacts.
The identification of the podosome regulatory protein Tks5
[21,41] as binding partner for b-dystroglycan and the demonstra-
tion that the two proteins were co-localised in podosome like
structures but not in focal adhesions, further substantiates the
identity of the adhesion structures in myoblasts as podosomes.
Activation of Src downstream of PDBu-mediated activation of
PKC leads to the phosphorylation of DG on Y890. Y890 is within a
potential SH3 domain interaction consensus PYVP, and as such
could be involved in a direct interaction with Tks5 through the 3rd
SH3 domain identified in the original proteomic screen. However as
Figure 7. Mutation of the DG phosphorylation site restores podosome formation. Myoblast cells were transiently transfected with
dystroglycan-GFP wild-type sequence, or containing the indicated point mutation in the cytoplasmic domain. Wild-type dystroglycan fully
suppressed podosome formation, whereas all mutant constructs partially suppressed the inhibition of podosomes by DG over-expression by around
20–30%, the Y890A mutation however, suppressed the inhibitory effect by over 70% compared to mock transfected controls. (mean6SEM). Inset
shows typical expression levels of the dystroglycan-GFP and mutants as judged by anti-GFP western blot from a representative transient expression.
doi:10.1371/journal.pone.0003638.g007
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co-immunoprecipitation of Tks5 and b-DG revealed that b-DG was
phosphorylated on Y890, it is likely that Tks5 interacts with a
different SH3 interaction site in dystroglycan as tyrosine phosphor-
ylation in this context would be likely to disrupt the SH3 domain
interaction. Furthermore overexpression of dystroglycan was able to
direct the localisation of Src away from the triton insoluble
cytoskeletal fraction and into the CHAPS soluble membrane and
cytoplasmic fraction. Thus we have demonstrated a binary complex
between dystroglycan and the Tks5 SH3 domain in vitro, and by
GST-affinity chromatography demonstrated that dystroglycan from
cell extracts can also bind the Tks5 SH3 domain, but in the cellular
context the dystroglycan recovered on these columns appears to be
phosphorylated on Y890. If the association of dystroglycan and
Tks5, whilst mediated at least in part by an SH3 interaction, is
strengthened by phosphorylation on Y890, this would suggest the
involvement of a third protein capable of interacting with Tks5 and
Figure 8. Src inhibition prevents dystroglycan localisation/podosome formation. Myoblast cells were seeded onto tissue culture plastic
and allowed to spread for one hour before fixation and staining for b-dystroglycan, F-actin and the indicated markers of cell adhesion. In A cells were
untreated and formed dystroglycan-containing puncta as before. Cells in B, were treated with the Src Inhibitor PP2 (10 mM) for 1 hour before and
during re-seeding. No dystroglycan-containing puncta were formed in these cells. Focal adhesions appeared to form as normal, as judged by staining
for paxillin, talin, vinculin and phospho-tyrosine (pTyr). Dystroglycan staining in green in all merged images. Scale bars 20 mm.
doi:10.1371/journal.pone.0003638.g008
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the potential SH2 domain interaction site on dystroglycan
generated by Y890 phosphorylation. Such a protein could be Src,
as both Tks5 and dystroglycan are substrates for Src [21,41,46] and
Src can bind to dystroglycan via an SH2 mediated interaction [46].
The redistribution of Src from triton insoluble to CHAPS soluble
fraction on dystroglycan overexpression, is also in agreement with a
Src-dystroglycan interaction. The distribution of Src between triton-
soluble and triton insoluble fractions is dependent on a number of
factors, including the cell type, the adhesion status of the cell,
extracellular matrix ligands, presence or absence of serum or other
factors that stimulate signalling cascades. Whilst often found
associated with the triton soluble fraction [57], growth of cells on
different extracellular matrix substrates can dramatically alter this
distribution [58]. In fibronectin-stimulated NIH3T3 fibroblasts for
example, active Src is almost exclusively recovered in the triton
insoluble fraction [59].
Finally, Tks5, Src and dystroglycan were recovered by
immunoprecipitation apparently as a ternary complex. Based on
Figure 9. Dystroglycan overexpression alters Src distribution. A. A representative blot of fractionation of DG, pDG and Src in control or DG-
GFP overexpressing cells; Ts, Triton soluble wash fraction; C, CHAPS soluble cytoplasmic/membrane fraction; Ti, Triton insoluble cytoskeletal fraction.
Quantification from 3 independent fractionation experiments of DG (B), pDG (D) and pan Src (C) in control or DG-GFP overexpressing cells revealed
an increase in pDG relative to total DG, and in the CGAPS soluble fraction relative to Triton insoluble cytoskeletal fraction, of DG overexpressing cells
(B,D) Most dramatic and unexpected is a complete shift of Src from Triton insoluble cytoskeletal fraction to CHAPS soluble membrane fraction on DG
overexpression (C). Immunoprecipitation from myoblast lysates with Tks5 or DG antibodies both revealed the presence of Src in the precipitated
fraction of both suggesting the presence of a DG/Src/Tks5 complex in myoblast cells (E).
doi:10.1371/journal.pone.0003638.g009
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this notion, one could postulate a potential mechanism for the
roles of Tks5 and DG in podosome assembly. Under normal
circumstances Tks5 and b-DG are not associated and not present
in podosomes or other adhesion structures. Following activation of
Src, DG is phosphorylated on Y890 creating an SH2 domain
interaction site leading to the recruitment of active Src to DG [46].
The dystroglycan-Src complex then also binds to Tks5 leading to
its phosphorylation and the participation of the whole complex in
the podosome assembly process. In the presence of excess
dystroglycan, for example when DG is over-expressed, DG can
still be phosphorylated by Src, but the excess DG in the cell
effectively titrates out the Src signal with respect to Tks5 levels,
thus reducing Tks5 phosphorylation and inhibiting podosome
formation. A 50% reduction in dystroglycan has a moderate effect
on podosome formation compared to overexpression, possibly
because it allows some dystroglycan:Src:Tks5 complexes to form
and these are sufficient to allow a limited number of podosomes to
form. However too much dystroglycan is completely inhibitory
due to the mislocalisation of Src likely reducing Tks5 phosphor-
ylation removing a key stimulus to podosome formation [21]. Tks5
has also recently been shown to be involved in other ternary
complexes that facilitate podosome formation. In Src-transformed
NIH3T3 (NIH-Src) cells, Tks5 was found to be associated with the
adaptor protein Grb2, and N-WASP a regulator of actin
polymerisation [60]. In this system, Src expression drives the
Grb2-Tks5 interaction which then associates with N-WASP via
numerous SH3 mediated interactions targeting actin polymerisa-
tion to sites of podosome formation. This and our study would
suggest that Tks5 is a multifunctional scaffold able to recruit other
adaptors, signalling, regulatory and adhesion proteins such as
dystroglycan to podosomes via its multiple SH3 domains.
Dystroglycan is therefore a new addition to the increasing
number of podosome components, though rather than a spectator
is appears to be a key player in the Src and Tks5-dependent
regulation of podosome formation in myoblasts. Moreover the
demonstration of podosome formation in myoblasts opens new
avenues to dissect cell migration during early stages of develop-
ment and in muscle repair, where myoblast cells and their
precursors travel large distances to populate newly developing
muscles or to mend damaged or diseased muscle.
Supporting Information
Figure S1 Localisation of dystroglycan and the indicated core
podosome proteins in H2k myoblasts (A), C2C12 myoblasts (B)
and A7r5 smooth muscle cells (C). Cells were stimulated to form
podosomes with PDBu and stained for the indicated adhesion
proteins or F-actin. In merged images dystroglycan is always green
and/or F-actin is always red.
Found at: doi:10.1371/journal.pone.0003638.s001 (10.06 MB
DOC)
Movie S1 H2k myoblast transiently expressing actin-GFP and
stimulated with PDBu. Frame interval in is 30 sec. Cell exhibits
dense but transient actin puncta - podosomes at the cell periphery
or more centrally beneath the nucleus in reponse to PDBu
stimulation.
Found at: doi:10.1371/journal.pone.0003638.s002 (0.72 MB
MOV)
Movie S2 H2k myoblast transiently expressing actin-GFP and
stimulated with PDBu. Frame interval in is 30 sec. Cell exhibits
dense but transient actin puncta - podosomes at the cell periphery
or more centrally beneath the nucleus in reponse to PDBu
stimulation.
Found at: doi:10.1371/journal.pone.0003638.s003 (1.24 MB
MPG)
Movie S3 H2k myoblast transiently expressing actin-GFP and
stimulated with PDBu. Frame interval in is 30 sec. Cell exhibits
dense but transient actin puncta - podosomes at the cell periphery
or more centrally beneath the nucleus in reponse to PDBu
stimulation.
Found at: doi:10.1371/journal.pone.0003638.s004 (1.41 MB
MPG)
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